Psoriasis - Pipeline Review, H1 2015

Psoriasis - Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Psoriasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Psoriasis - Pipeline Review, H1 2015

Scope

- The report provides a snapshot of the global therapeutic landscape of Psoriasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Psoriasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

4SC AG AbGenomics International, Inc. Acceleron Pharma, Inc. Actelion Ltd Addex Therapeutics Ltd Advinus Therapeutics Ltd. Ajinomoto Pharmaceuticals Co., Ltd. AlbireoPharma Allozyne, Inc. Almirall, S.A. AlphaMab Co., Ltd Amgen Inc. Anacor Pharmaceuticals, Inc. Apexigen, Inc. ApoPharma Inc. Arena Pharmaceuticals, Inc. Argos Therapeutics, Inc. Arrien Pharmaceuticals, LLC AuraSense Therapeutics, LLC Avesthagen Limited Avexxin AS Basilea Pharmaceutica AG BIOCAD Biocon Limited Bionomics Limited Biotest AG Biotie Therapies Corp. Boehringer Ingelheim GmbH Brickell Biotech, Inc. Can-Fite BioPharma Ltd. Celgene Corporation Cellceutix Corporation Celltrion, Inc. ChemoCentryx, Inc. ChironWells GmbH Circassia Pharmaceuticals plc Coherus BioSciences, Inc. Compugen Ltd. Convoy Therapeutics, Inc. Covagen AG Creabilis SA Crescendo Biologics Limited Delenex Therapeutics AG Deltanoid Pharmaceuticals Inc. Dermira Inc. Effimune SAS Eli Lilly and Company Epirus Biopharmaceuticals, Inc. Farmacija d.o.o. Tuzla Fibrocell Science, Inc. Foamix Pharmaceuticals Ltd. Forward Pharma A/S Gem Pharmaceuticals, LLC Gene Signal International SA Genentech, Inc. Genor BioPharma Co., Ltd. GlaxoSmithKline plc GliaCure Inc. GlycoMar Limited Grupo Ferrer Internacional, S.A. Hydra Biosciences, Inc. Idera Pharmaceuticals, Inc. Immune Response BioPharma, Inc. Invion Limited ISDIN Johnson & Johnson Kadmon Corporation, LLC KaloBios Pharmaceuticals, Inc. Kineta, Inc. Kinex Pharmaceuticals, LLC Kyowa Hakko Kirin Co., Ltd. Lee's Pharmaceutical Holdings Limited LegoChem Biosciences, Inc LEO Pharma A/S Lipidor AB Lupin Limited Lycera Corp. Mabion SA Maruho Co., Ltd. MediGene AG Merck KGaA Mitsubishi Tanabe Pharma Corporation NovaLead Pharma Pvt. Ltd. Novartis AG Oncobiologics, Inc. Ono Pharmaceutical Co., Ltd. OPKO Health, Inc. Panacea Biotec Limited Pfizer Inc. Pharis Biotec GmbH Pharmedartis GmbH Phenex Pharmaceuticals AG Pieris AG PinCell srl Promius Pharma, LLC Protalix BioTherapeutics, Inc. Prothena Corporation plc Provectus Biopharmaceuticals, Inc. PurGenesis Technologies Inc. R-Tech Ueno, Ltd. RedHill Biopharma Ltd. RestorGenex Corporation Rigel Pharmaceuticals, Inc. Salix Pharmaceuticals Ltd. Sandoz International GmbH Sareum Holdings plc Selvita SA Sigmoid Pharma Limited Soligenix, Inc. Spherium Biomed S.L. sterna biologicals Gmbh & Co KG Sun Pharma Advanced Research Company Ltd. Sun Pharmaceutical Industries Inc. SWITCH Biotech LLC Syntrix Biosystems, Inc. Takeda Pharmaceutical Company Limited Telormedix SA TetraLogic Pharmaceuticals Teva Pharmaceutical Industries Limited Therapix Biosciences Ltd Tolero Pharmaceuticals, Inc. UCB S.A. Uni-Bio Science Group Ltd. Valeant Pharmaceuticals International, Inc. Virobay Inc. Vitae Pharmaceuticals, Inc. Welichem Biotech Inc. XBiotech USA, Inc. XenoPort, Inc. Ziarco Pharma Ltd

Contact:
Debora White
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research